Influenza virus assays based on virus-inducible reporter cell lines

Yunsheng Li, Audrey Larrimer, Teresa Curtiss, Jaekyung Kim, Abby Jones, Heather Baird-Tomlinson, Andrew Pekosz, Paul D. Olivo

aDiagnostic Hybrids Inc., Athens, OH, USA. bW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.

Correspondence: Paul D. Olivo, MD, PhD, 1055 State St. Athens, OH 45701, USA. E-mail: paul_olivo@dhiusa.com

Accepted 12 June 2009. Published Online 13 July 2009.

Background Virus-inducible reporter genes have been used as the basis of virus detection and quantitation assays for a number of viruses. A strategy for influenza A virus-induction of a reporter gene was recently described. In this report, we describe the extension of this strategy to influenza B virus, the generation of stable cell lines with influenza A and B virus-inducible reporter genes, and the use of these cells in various clinically relevant viral assays. Each of the cell lines described herein constitutively express an RNA transcript that contains a reporter gene coding region flanked by viral 5'- and 3'-untranslated regions (UTR) and therefore mimics an influenza virus genomic segment. Upon infection of the cells with influenza virus the virus-inducible reporter gene segment (VIRGS) is replicated and transcribed by the viral polymerase complex resulting in reporter gene expression.

Findings Reporter gene induction occurs after infection with a number of laboratory strains and clinical isolates of influenza virus including several H5N1 strains. The induction is dose-dependent and highly specific for influenza A or influenza B viruses.

Conclusions These cell lines provide the basis of simple, rapid, and objective assays that involve virus quantitation such as determination of viral titer, assessment of antiviral susceptibility, and determination of antibody neutralization titer. These cell lines could be very useful for influenza virus researchers and vaccine manufacturers.

Keywords Influenza virus, neutralizing antisera, reporter cell lines, virus detection.

Please cite this paper as: Li et al. (2009) Influenza virus assays based on virus-inducible reporter cell lines. Influenza and Other Respiratory Viruses 3(5), 241–251.

Introduction

Influenza causes considerable morbidity and mortality in the human population worldwide. Annual outbreaks in the United States claim over 36,000 lives and cost billions of dollars.1,2 Antiviral therapy is available, but the emergence of human H1N1 viruses that are resistant to oseltamivir and human H3N2 viruses resistant to amantadine4 have raised concerns about the use of these antivirals. Vaccination remains the most effective defense against influenza2,6 but the process of vaccine strain selection and antigenic drift of human influenza A virus isolates has led to mismatches between vaccines and circulating virus strains.7 The threat of another influenza A virus pandemic is a continued concern, particularly because of increasing exposure of humans to avian and swine strains of influenza A virus.8-10

Accurate, specific, and rapid detection and quantification of influenza virus are critical for successful development of diagnostic tests, antiviral drugs and vaccines. Assays that are based on virus-induced cytopathic effects such as the plaque forming unit (pfu) and the tissue culture infectious dose (TCID50) are still commonly used to quantify influenza virus, but such assays are time-consuming and labor-intensive. Antibody neutralization assays which are used for studies of vaccine efficacy include the hemagglutination inhibition assay and the microneutralization assay, share similar limitations.12,13 Considerable effort has been devoted to improve methods of cell-based antiviral influenza drug screening using a colorimetric or fluorometric readout that is based on inhibition of virus-induced cytotoxicity. In one such method a cell viability assay, which measures ATP via a luciferase luminescence system, was shown to give comparable results to the use of a neutral red assay.14

Cell lines containing a virus inducible reporter gene have been used successfully to detect retroviruses such as Human Immunodeficiency virus (HIV),15-17 DNA viruses such as Herpes Simplex Virus (HSV)18-22 and RNA
viruses such as respiratory syncytial virus (RSV). Recently, a detection system for influenza A virus was developed based on a virus-inducible reporter gene segment (VIRGS). These preliminary studies with transiently transfected cells demonstrated the potential of this approach to detect and quantify influenza A virus using a luciferase or green fluorescent protein (GFP) reporter gene system. These findings prompted us to generate permanent cell lines using linearized plasmid DNA integrated into the host cell chromosome. In this study, we demonstrate the utility of these cell lines in objective, rapid, and quantitative assays for virus quantification, virus neutralization assays, and drug screening assays. We have applied the acronym enzyme-linked virus inhibitor reporter assay (ELVIRA) for this technology and our cell lines as ELVIRA® Flu A or Flu B (Diagnostic Hybrids, Inc., Athens, OH, USA).

Materials and methods

Plasmid construction

Plasmids that contain virus-inducible reporter genes were constructed as described in Lutz et al. Briefly, the 5’- and 3’-UTRs of the influenza A virus (A/WSN/33 H1N1) NP genomic segment were inserted between the human polymerase I promoter and the terminator elements in plasmid pHH21 using the following two partially complementary oligonucleotides that contain the 5’- (red) and 3’- (blue) untranslated regions of the NP segment:

1. 5’-TATTAGTAGAAAACAGGTTATTTTCTGTAAAA CTATTACCGATGTCATCAGTGATGTTATCTACC CTTTTTCTAC-3’
2. 5’-GGGATGAGAAAACAGGTTAGATAATACCTACCTAGT GACATCGGTAAAGTTTAACAGAAAATATCCCC TTGTGTTTAC-3’

The oligonucleotides were designed so that after annealing there would be a 3 or 4-base 5’-overhang on each end to allow ligation to the Bsm BI site in pHH21 and a Pme I restriction site between the two UTR elements for insertion of the reporter genes. The firefly luciferase (pGL-2-Basic; Promega, Madison, WI, USA) or GFP (pEGFP-1; Clontech, Mountain View, CA, USA) reporter genes were inserted into the Pme I site of the resultant pHH21/UTR plasmid. The Pol I promoter/UTR/reporter gene cassette was removed from the above vector and inserted into the pRep4 vector. Finally, the EBV origin of replication and EBNA-1 gene were deleted from the plasmid with restriction endonucleases Ssp I and Sph I to generate plasmids pHH21influenza A virus/Luc-Hyg and pHH21influenza A virus/GFP-Hyg. A similar strategy was used for the influenza B virus UTRs from the NP segment of the B/Yamanashi strain. Four oligomers were used and linked to make a 174 base pair oligonucleotide shown below as two partially complementary oligonucleotides:

1. 5’-GGGAGCAGAAGCAGACATTTCTGTGAACCT CAAGTACCAATAAAAAGAACTGAAATTCAAGTT TAAAAGCACAATAATTAGCAGATGCTGTGATT GTTTCAATAGTTTGGAGTGCGTTTACTCTTA TTAAAAATATAAAAACTGTGGTCTTACT-3’
2. 5’-TATTAGTAGAAAACAGGCTATTTTTATATTAT TTTAAAAGATAAACCACCATCTCAGAAACTGAT TGAACATACCGCATGTTCTTTTGTGGC TGTTTGAACTTTGTATTTGCTTATTGAT AACTTGAAGTTCCAAAGAAAATGCTGCTTCTGCT-3’

Red-colored letters are B/Yamanashi NP 5’-UTR (62 bases). Blue color letters are B/Yamanashi NP 3’-UTR (101 bases). As with the influenza A virus cloning strategy after annealing the duplex oligonucleotide has a 3 or 4-base 5’-overhang on each end to allow ligation to the Bsm BI site in pH21 and a Pme I restriction site between the two UTR elements for insertion of the reporter genes renilla luciferase (phRL-TK; Promega) and GFP to generate plasmids pHH21influenza B virus/Luc-Hyg, and pHH21influenza B virus/GFP-Hyg.

Cells

Human kidney 293T cells (American Type Culture Center, Manassas, VA, USA) were grown in Dulbecco’s modified Eagle’s medium containing 4% or 10% fetal bovine serum, 2 mm of glutamine and 50 μg/ml of gentamicin at 37°C with 5% CO₂. Madin-Darby Canine kidney (MDCK) cells (ATTC) were grown in the same medium as the 293T cells.

Transfection and selection of the ELVIRA® Flu A and Flu B cell lines

293T cells, plated in two wells of a 24-well plate, were transfected with linearized pHH21influenza A virus/Luc-Hyg, pHH21influenza B virus/Luc-Hyg, pHH21influenza A virus/GFP-Hyg and pHH21influenza B virus/GFP-Hyg using Hyfect (Denville Scientific Inc., Metuchen, NJ, USA) according to the manufacturer’s instructions. After incubation for 24 hours at 37°C the cells were trypsinized and serially diluted into 96-well plates. The transfected cells were cultured in media containing 150 μg/ml hygromycin B (Invitrogen Corporation Carlsbad, CA, USA). After colonies were observed, they were transferred into a single well of a 24-well plate. When the monolayer was confluent, the cells of each colony were passed into four wells in two separate 24-well plates. One plate was maintained in the culture medium and incubated at 37°C. One well from each colony of the other plate was either infected with influenza A virus or influenza B virus or used as an uninfected control. Twenty-four hours after virus infection, luciferase activity or GFP fluorescence was measured. The cells from colonies with a high infected-to-uninfected ratio of lucifer-
ase or GFP activity were selected for further subcloning. Selected clones were plated in 96-well plates at an average 0.5 cell/well and cultured in medium containing 150 μg/ml hygromycin B to obtain isolated clonal cell lines.

**Virus strains and virus infection**

Virus strains including influenza A and B and other respiratory viruses were obtained from ATCC; CDC, Atlanta, GA, USA; Ohio Department of Health, Alliance, OH, USA; Seattle & King County Public Health Laboratory, Seattle, WA, USA; Iowa Methodist Hospital Des Moines, Iowa; and Riley Hospital for Children, Indianapolis, Indiana. The H5N1 strains were supplied by Battelle and experiments with these strains was performed in their biosafety level 3 facility in Columbus, OH, USA.

Nearly, confluent monolayers of ELVIRA® Flu A or Flu B cells were infected with influenza A or B or other respiratory virus with the indicated multiplicity-of-infection (MOI). Virus infections were performed in the presence of Opti-MEM medium containing 0.5 μg/ml trypsin. Following virus inoculation, the cells were centrifuged for 1 hour at 700 g and incubated in 37°C with 5% CO₂ for 20–24 hours. The amount of the virus inocula were confirmed by simultaneous infection of R-mix monolayers (Diagnostic Hybrids Inc.) which contain Mv1Lu and A549 cells or by infection of the ELVIRA® Flu A-luc cell line followed by immunostaining with anti-influenza antibodies (Diagnostic Hybrids Inc.) after 20–24 hours.

**Luciferase assays**

Virus-infected ELVIRA® Flu A-luc cells were lysed and analyzed for firefly luciferase activity using the Bright-Glo Luciferase Assay System (Promega). ELVIRA® Flu B-Rluc cells were lysed and analyzed for activity using the Renilla Luciferase Assay System (Promega). A Veritas Luminometer (Turner BioSystems, Sunnyvale, CA, USA) was used to measure relative light units (RLU) according to the manufacturers’ instructions.

**GFP time course study**

The ELVIRA® Flu A-GFP and Flu B-GFP cell lines were assessed for reporter gene expression by visual examination of the monolayer at 6, 19, 48, and 72 hours post-infection under a Nikon Eclipse TS100 fluorescent light microscope at 100× magnification (Nikon, Melville, NY, USA). The light source for the microscope was a Mercury-100W (Chiu Technical Corporation, Kings Park, NY, USA) and the image was captured with QCapture 2.70.0 software (Quantitative Imaging Corporation, Surrey, BC, Canada).

**Neutralization assay**

Influenza A/WSN/33 virus (5000 infectious units) or A/Wisconsin/56/2005 (500 infectious units/well) were incubated for 2 hours at 37°C with twofold serially diluted mouse anti-A/WSN/33 and human sera, respectively. All the sera samples were heated at 56°C for 30 minutes prior to the incubation with virus. The virus-serum mixture was then added to monolayers of ELVIRA® Flu A-luc cells grown in 96-well plates. Cells were lysed and the cell lysates were analyzed for luciferase activity 24 hours post-infection. The percent reduction of luciferase activity, measured as RLU of wells with serum-treated virus compared with the virus-only controls, was calculated. The reciprocal of the dilution that resulted in a reduction of 99% or greater was recorded as the neutralization titer.

**Hemagglutination Inhibition assay**

Influenza A/Wisconsin/56/2005 (4 HA units = 115,000 infectious units/well) was incubated with twofold serially diluted human sera for 1–2 hours at 37°C in 96-well plates. Then 1% guinea pig red blood cells (RBCs) (Colorado Serum Co., Denver, CO, USA) were added to the virus-serum solution and mixed. The plates were read after 30 minutes incubation at room temperature.

**Determination of virus titer**

ELVIRA® Flu A-luc and MDCK cells were grown in 96-well plates to 90–100% confluence. The cells were washed once with serum-free medium or phosphate-buffered saline. Nine serial 10-fold dilutions of influenza A virus were made with serum free medium. Dilutions 10⁻⁴ through 10⁻⁸ were used to inoculate 10 wells of each cell type. The plates were centrifuged for 1 hour at 700 g after infection and then incubated at 37°C with 5% CO₂. ELVIRA® Flu A-luc cell lysates were analyzed for luciferase activity 24–48 hours after infection. MDCK cells were observed for cytopathic effects (CPE) 4–6 days after infection. ELVIRA® Flu A-luc wells were considered positive for viral infection if their RLU value was >3 times the mean background RLU value. The 50% tissue culture infectious dose (TCID₅₀) was determined by the Reed & Muench method.²⁷

**Measurement of antiviral activity using ELVIRA® Flu A cells**

The ELVIRA® Flu A-luc cells were used to assess the inhibition of influenza A by various concentrations of amantadine (Sigma-Aldrich, St Louis, MO, USA) or bafilomycin. The cells were plated in 96-well plates as described above and incubated with serial dilutions of the drugs for 15 minutes (amantadine) or 30 minutes (bafilomycin) at 37°C. Influenza A virus (10 000 infectious units) was added to wells containing amantadine (A/ODH 154 infected cells) or bafilomycin (A/Wisconsin/56/2005 infected cells). Plates were centrifuged at 700 g for 1 hour and then incubated at 37°C with 5% CO₂ for 24 hours followed by measurement.
of luciferase activity. The concentration of drug that reduced the RLU by 50% compared with the no-drug control was calculated and reported as the IC_{50} value.

Results

Detection of influenza A and B viruses using ELVIRA® cells

Stable human kidney 293T cell lines that constitutively express a negative-sense RNA encoding the firefly luciferase gene (luc) or the GFP gene flanked by the untranslated regions (UTR) of the NP segment of influenza A virus (A/WSN/33) UTRs or influenza B virus (B/Yamanashi) were generated as described in the Materials and methods section. The virus-inducible reporter gene in these cells is expressed under the control of the human RNA polymerase I promoter/terminator sequences.\(^28,29\) The human polymerase I promoter is species-specific which required that the parental cell line be of human origin. These cell lines have been cultured for 50 passages with no appreciable loss of inducible reporter gene expression.

Virus-inducible reporter gene expression from the ELVIRA® Flu A-luc and ELVIRA® Flu B-Rluc cell lines was assessed after infection with influenza A and B viruses respectively at high and low MOI. At various times after infection cells were lysed and luciferase activity was measured (Figure 1). The graphic display of the data reveals classic single and multistep viral growth kinetics and a time course very similar to infectious virus production on these cells. These results reveal that measurement of luciferase activity provides a valid surrogate marker of virus replication.

A virus dose–response was performed by infecting the ELVIRA® Flu A-luc and ELVIRA® Flu B-Rluc cell lines with various amounts of influenza A and B viruses and measuring luciferase activity after 24 hours (Figure 2). For both cell lines there was a linear dose–response curve with a wide dynamic range. This result suggested that this methodology can be used to accurately titer virus stocks. We next determined the titer of stocks of several influenza A and B virus strains using the ELVIRA® Flu A-luc and ELVIRA® Flu B-Rluc cells and determined the titers at

![Figure 1](image)

Figure 1. Time course of luciferase expression of ELVIRA® Flu A-luc or Flu B-Rluc cells following infection with influenza viruses. ELVIRA® Flu A-luc or Flu B-Rluc cells were infected with influenza A/WSN/67/05 or influenza B/Malaysia2506/04 at the indicated MOI. Luciferase activity was measured at various time points after virus infection and expressed as RLU/well. Results shown are mean of 3 replicates. (A) Luciferase activity of ELVIRA® Flu A-luc cells infected with influenza A/WSN/67/05. The insert shows data from the early time points. (B) Luciferase activity of ELVIRA® Flu B-Rluc cells infected with influenza B Malaysia2506/04.
the same time with MDCK cells using a TCID₅₀ method. We included in this analysis four strains of highly pathogenic avian (H5N1) influenza A virus which all were able to induce luciferase in the ELVIRA® Flu A-luc cells (data not shown). As shown in Table 1 the titers generated with both cell lines were very similar.

In addition to cell lines that express virus-inducible luciferase, we generated cell lines that express GFP following influenza virus infection using the same strategy. Figure 3 shows the absence of GFP expression in mock-infected cells and a high level of expression in the cytoplasm of influenza A virus-infected ELVIRA® Flu A-GFP cells and influenza B virus-infected Flu B-GFP cells. No cross-induction was observed. These cells could be useful in methods for which there is an advantage to using either live or intact cells (i.e., cells that are not lysed).

**Specificity of virus-induced luciferase expression from ELVIRA® Flu A-luc cells**

We tested a panel of influenza A virus and influenza B virus isolates including H3N2 and H1N1 types on the ELVIRA® Flu A-luc cells. All influenza A virus isolates induced high levels of luciferase with signal-to-noise ratios ranging from 20 to over 1000 (Table 2). Influenza A virus triggered luciferase in the ELVIRA® Flu B-Rluc cells, but at a low level. One isolate of influenza B virus (B/Taiwan) induced a low level of luciferase, but two others did not induce activity in the ELVIRA® Flu A-luc cells above background (Table 2). Both cell lines were also infected with a panel of unrelated respiratory viruses at a high MOI. Twenty-four hours after infection, luciferase expression was essentially the same as background and the signal-to-noise was never higher than two (Table 2).

**Measurement of neutralizing antibody using ELVIRA® cells**

The results of Figure 2 show that luciferase activity is proportional to the virus inoculum and suggest that this system could be applied to any influenza assay that depends on a quantitative assessment of virus infectivity. We therefore tested the usefulness of this system to titer neutralizing serum. Dilutions of immune or non-immune mouse sera were added to a fixed amount of influenza virus. As shown in Figure 4 immune serum reduced luciferase activity in a

---

**Figure 2.** Dose-response of luciferase expression of ELVIRA® Flu A-luc or ELVIRA® Flu B-Rluc detecting cell line following infection with either influenza A or B virus. Cell lines were infected with their corresponding virus and analyzed for luciferase activity 24 hours after infection (RLU/well). Results are the average of triplicates ± SD. (A) Luciferase activity of ELVIRA® Flu A-luc cell line after infection with 12 different amounts of Influenza A/Wisconsin67/05 from 100–75 000 infectious units. (B) Luciferase activity of ELVIRA® Flu B-Rluc cell line infected with seven different concentrations of influenza B/Malaysia/2506/04 ranging from 100 to 7500 infectious units.
we compared serum that resulted in at least a 99% reduction in luciferase recorded the titer as the reciprocal of the lowest dilution of dose-dependent manner to nearly background levels. We recorded the titer as the reciprocal of the lowest dilution of serum that resulted in at least a 99% reduction in luciferase compared with the virus-only control. We then compared the use of this assay to a hemagglutination inhibition assay to assess neutralization titer of nine human sera against influenza A virus (A/Wisconsin/56/2005) and five sera against influenza B virus (B/Malaysia2506/04). As shown in Table 3, the titers were comparable, although not identical which is not uncommon when comparing microneutralization to HI.30

### Antiviral susceptibility testing of influenza A and B viruses using ELVIRA® cells

The applicability of this methodology for antiviral susceptibility testing was also evaluated. Figure 5 shows the effect of various concentrations of two known anti-influenza compounds on virus-induced luciferase expression. The graphic display of the results shows classic sigmoidal curves and the IC_{50} determinations calculated using this method were similar to results reported in the literature for amantadine-sensitive influenza strains.31 Influenza B virus is resistant to amantadine and this is reflected in the lack of reduction of luciferase expression following amantadine treatment of infected ELVIRA® Flu B-Rluc cells (Figure 5D).

### Discussion

Accurate, specific, and rapid identification and quantification of influenza virus is an important component of influenza research, antiviral drug discovery, and vaccine development. New technologies that promote these goals will result in the development of better drugs and vaccines to control seasonal influenza and hopefully prevent or lessen the impact of a pandemic. In this study, we describe the successful establishment of stable cell lines engineered to contain influenza virus-inducible reporter genes. These cells form the basis of rapid and objective assays that can be used to measure the titer of infectious virus, the titer of

| Virus strain | Method* | ELVIRA | Flu A Luc | MDCK |
|--------------|---------|---------|-----------|------|
| A/Philadelphia/59/2007 (H1N1) | 1:08E + 07 | 1:26E + 07 |
| A/Solomon island/03/2006 (H1N1) | 1:58E + 07 | 1:99E + 07 |
| A/Wisconsin/56/2005 (H3N2) | 1:80E + 07 | 1:19E + 07 |
| A/Malaysia/302/54 (H1N1) | 2:59E + 07 | 8:89E + 06 |
| A/Whooperswan/Mongolia/244/05 (H5N1) | 1:78E + 08 | 1:2E + 08 |
| A/Hong Kong/483/97 (H5N1) | 5:01E + 07 | 2:51E + 06 |
| A/Hong Kong/486/97 (H5N1) | 2:09E + 08 | 1:17E + 07 |
| A/Vietnam/1203/04 (H5N1) | 2:57E + 07 | 3:31E + 07 |
| B/Malaysia2506/04 | 5:00E + 07 | 2:32E + 07 |
| B/GL/1739/S4 | 5:00E + 05 | 1:25E + 06 |
| B/Florida04/2006 | 5:00E + 06 | 2:59E + 06 |

*Ten-fold serial dilutions of influenza A or B virus stocks were made in serum free medium. ELVIRA Flu A and MDCK cells were planted in 96-well plates and then infected with the 10^{-4} through 10^{-6} dilutions (10 wells/dilution). After infection, the cells were incubated at 37°C with 5% CO₂ for 24 or 48 hours (ELVIRA cells) or 4 days (MDCK cells). ELVIRA Flu A luc and ELVIRA Flu B Rluc wells with a RLU reading of >3 times the background mean were considered positive for influenza infection. MDCK cells were inspected microscopically for cytopathic effects. TCID₅₀ was calculated by the Reed & Muench method.

Figure 3. Photomicrographs (100x) showing GFP expression from ELVIRA® Flu-GFP cell lines infected with influenza A or B viruses. GFP-expressing cells were detected by fluorescent microscopy at 24 or 48 hours after infection. (A) The ELVIRA® Flu A-GFP cell line was infected with influenza A virus strains A/Wisconsin/67/05 and A/MHIA0009, and influenza B virus strains B/Maryland/1/59 (ATCC VR-296) and B/Massachusetts (ATCC VR-523) at 1 MOI. Photomicrographs were taken at 24 hours after infection. (B) The ELVIRA® Flu B-GFP cell line was infected with influenza B virus B/ODH0149 and B/GL/1739/S4 at 0.5 MOI and influenza A virus influenza A virus A/MHIA0009 and A/PortChalmers/1/73(H3N2) at 1 MOI. Photomicrographs were taken at 48 hours after infection.

246 © 2009 Blackwell Publishing Ltd, Influenza and Other Respiratory Viruses, 3, 241–251
neutralizing antibody, and the susceptibility of influenza virus strains to antiviral drugs.

The concept of VIRG was described a number of years ago and was first successfully applied to influenza viruses by Lutz et al. In this proof-of-concept report influenza virus-dependent reporter gene expression was demonstrated using an RNA segment that was transcribed from a human polymerase I promoter and contained a reporter gene flanked by untranslated regions (UTRs) from the influenza nucleoprotein (NP) RNA segment. Unfortunately, the transient and the episomal expression systems used in this previous work have drawbacks when attempting to apply this technology to robust and reliable assays that could be used for industrial or clinical applications. In this report, we generated stably transformed cell lines and demonstrated that these cell lines can be maintained for many passages without loss of their phenotype with respect to virus-induction of the reporter gene. We have also extended the technology to influenza B virus which is a component of most influenza vaccines and which contrib-

### Table 2. Specificity of ELVIRA® Flu A* (A) or Flu B** (B) cell lines following infection with influenza A, influenza B, or unrelated respiratory viruses

| Virus          | Strain/sample | Source                  | Ave RLU (n = 3) | STDEV | S/B |
|----------------|---------------|-------------------------|-----------------|-------|-----|
| **A**          |               |                         |                 |       |     |
| Parainfluenza 1| Clinical isolate | Health alliance | 195             | 10    | 1:3 |
| Parainfluenza 2| Clinical isolate | Health alliance | 280             | 6     | 1:9 |
| Parainfluenza 3| Clinical isolate | Health alliance | 222             | 15    | 1:3 |
| hMPV***        | Clinical isolate (A1) | Italy    | 135             | 25    | 0:8 |
| hMPV           | Clinical isolate (A2) | Italy    | 217             | 8     | 1:3 |
| hMPV           | Clinical isolates (B1) | Italy    | 126             | 8     | 0:7 |
| Parainfluenza 3| C-243          | ATCC VR-93               | 141             | 20    | 0:9 |
| Parainfluenza 4b| CH 19503      | ATCC VR-1377             | 166             | 12    | 1:1 |
| Parainfluenza 2| Greer          | ATCC VR-92               | 193             | 11    | 1:3 |
| RSV†           | Long           | ATCC VR-26               | 151             | 16    | 0:5 |
| Parainfluenza 4a| M25           | ATCC VR-1378             | 143             | 17    | 1   |
| Adenovirus     | Clinical isolate (MHIA-0021) | Methodist Hospital | 160             | 18    | 1:1 |
| Adenovirus     | Type 5         | ATCC VR-5                | 114             | 13    | 0:8 |
| RSV            | WC-192         | West Chester             | 134             | 10    | 0:5 |
| Coronavirus     | 229E           | ATCC VR-740              | 147             | 38    | 1:1 |
| Coronavirus     | OC-34          | ATCC VR-1558             | 139             | 5     | 1   |
| Influenza B     | B/Massachusetts | ATCC VR-523              | 154             | 10    | 0:5 |
| Influenza B     | Clinical isolate B/MHIA-0023 | Methodist Hospital | 160             | 18    | 1:1 |
| Influenza B     | B/Taiwan       | ATCC VR-295              | 5247            | 222   | 16:7|
| Influenza A     | A/ODH 0023     | Ohio Department of Health | 455481         | 26225 | 1098|
| Influenza A     | A/Hong Kong/8/68 (H3N2) | ATCC VR-544             | 541988          | 18149 | 240 |
| Influenza A     | A/Mai/302/54 (H1N1) | ATCC VR-98             | 922701          | 17436 | 409 |
| **B**          |               |                         |                 |       |     |
| Adenovirus     | Type 5         | ATCC VR-5                | 27              | 2     | 2:1 |
| Parainfluenza I| C-35           | ATCC VR-94               | 10              | 1     | 0:8 |
| Parainfluenza II| Greer         | ATCC VR-92               | 12              | 1     | 0:9 |
| RSV            | Long           | ATCC VR-26               | 22              | 2     | 1:7 |
| Influenza A     | A/Denver/1/57 (H1N1) | ATCC VR-546            | 38              | 7     | 2   |
| Influenza A     | A/PortChalmers/1/73(H3N2) | ATCC VR-810           | 1004            | 27    | 41  |
| Influenza A     | A/WS/33 (H1N1) | ATCC VR-1520             | 270             | 74    | 11  |
| Influenza B     | Clinical isolate B/ODH0149 | Ohio Department of Health | 245825         | 2140  | 18910|
| Influenza B     | B/Malaysia2506/04 | CDC                | 134920          | 6839  | 9637|
| Influenza B     | B/GL/1739/54   | ATCC VR-823             | 151492          | 8412  | 10821|

*ELVIRA® Flu A-luc cells were infected with seventeen non-influenza respiratory viruses and three strains of influenza B viruses (MOI = 1) and three strains of influenza A (MOI = 0:1) were used as a positive control. The cells were assayed for luciferase activity 24 hours post-infection.

**ELVIRA® Flu B-Rluc cells were infected with four non-influenza respiratory viruses and three strains of influenza A viruses (MOI = 1) and three strains of influenza B virus (MOI = 0:5). The cells were analyzed for luciferase activity 24 hours post-infection.

***Human metapneumovirus.

†Respiratory syncytial virus.
Induced luciferase activity of ELVIRA/C210 was shown that activity for the type B polymerase machinery higher than by the heterologous virus. In a recent report, it but the induction by the homologous virus was many-fold level of cross-induction between influenza A and B viruses, luciferase activity above background levels. There was some viruses we inoculated onto the cell lines induced significant using a panel of respiratory viruses. None of the respiratory strains an empiric assessment of the ability of the virus to approach will be easily applied. For detection of unknown applications the strain of virus is known and this standard curve must be generated for each strain, but for on knowing how much virus is in a sample. Of course, a surrogate marker for virus amount in assays that depend This observation allows the use of reporter enzyme levels and that the levels of activity differ between type B strains.33 Using plasmid transfection they observed that type B polymerase machinery that is composed of homologous subunits is functional with a type A promoter albeit to a variable extent depending upon the segments from which the regions downstream of the promoter sequence were derived. These authors did not assess delivery of the polymerase genes by virus infection which may explain the greater specificity we observed.

Titration of influenza virus is often performed on MDCK cells by endpoint dilution, observation of CPE and calculation of the TCID$_{50}$. We determined the titer of stocks of a number of strains of influenza A virus including five H5N1 strains by using the TCID$_{50}$ method and by using either ELVIRA® Flu A-luc cells with luciferase as the readout or MDCK cells with CPE as the readout. The titers determined with the two methods were very similar despite the fact that there may be differences in susceptibility of the two cell lines to the virus strains tested. More strains need to be tested to support the use of the ELVIRA® Flu A-luc cells for this purpose, but there are clear advantages in terms reduced time to result (e.g., 1–2 days versus 4–6 days), greater objectivity, and less labor.

Titration of neutralizing antibody is an assay that can potentially benefit from use of these cell lines. It is clear that the induction of reporter enzyme depends on infectious virus. Using immunized mouse serum we demonstrated that the neutralizing activity of antisera can be identified as a function of the reduction in luciferase activity and that titers can be calculated based on a 99% inhibition. The HI assay is currently the gold standard for measurement of immunity following vaccination. Comparison of neutralization titers between the two methodologies showed a reasonable correlation though it is not surprising that the titers were not identical given that each assay measures neutralization in a very different manner. The assay described in this report offers a number of advantages over other virus neutralization assays that are based on various endpoints.$^{34,35}$

Finally, we applied this technology to an assessment of antiviral susceptibility. We observed excellent dose–response when measuring luciferase activity versus drug concentration for two antiviral compounds that have a mechanism of action that acts after virus entry.$^{31}$ Calculated IC$_{50}$ values were very similar to published reports using the amantadine-sensitive virus strains. We have not used this method for neuraminidase inhibitors. However, the results suggest that the ELVIRA® Flu A-luc cells could be used for screening of novel antiviral agents and for quantifying antiviral potency. Identification of new antiviral lead compounds depends on robust primary assays for high-throughput screening of large libraries of compounds.

**Figure 4.** The effect of neutralizing antibody on influenza A virus-induced luciferase activity of ELVIRA® Flu A-luc cells. Naive and immunized mouse sera were heat-treated at 56°C for 30 minutes and then serial diluted from 1:10 to 1:640 (non-immune serum) and 1:10 to 1:2560 (immune serum). Influenza A virus (WS/33; H1N1) (5000 infectious units) was incubated 1:1 (vol/vol) with each dilution of the sera for 60 minutes at room temperature. The virus was then used to infect ELVIRA® Flu A-luc cells and luciferase activity was measured after 24 hours. (A) Data expressed as total RLU per well. (B) Data expressed as a percentage of luciferase activity in virus-only wells.
Methods have also been developed for rapid evaluation of compounds for antiviral activity in 96-well microplates, which include visual quantitation of antiviral activity based upon inhibition of virus-induced CPE or by less subjective colorimetric or fluorometric means. A cell-based screen for potential influenza antivirals that measures the CPE

| Table 3. Comparison of antibody serum neutralization titers against influenza A virus (A) and influenza B virus (B) obtained using ELVIRA® Flu A-luc and Flu B-Rluc cells and Hemagglutination inhibition |
| --- |
| **A.** |
| Serum | ELVIRA Flu A* | HI** |
| Neg | <10 | 1280 |
| 1 | 1280 | 160 |
| 2 | 1280 | 80 |
| 3 | 1280 | 640 |
| 4 | 1280 | 1280 |
| 5 | 1280 | 1280 |
| 6 | 1280 | 1280 |
| 7 | 1280 | 1280 |
| 8 | 1280 | 1280 |
| **B.** |
| Serum | ELVIRA Flu B*** | HI† |
| 1 | <10 | 10 |
| 5 | 40 | 9 |
| 8 | 80 | 80 |
| 9 | 80 | 80 |
| 10 | 80 | 80 |

*ELVIRA Flu A-luc cells were infected with A/Wisconsin/56/2005 (500 infectious units/well) that had been incubated for 2 hours with dilutions (1:10 followed by twofold serial dilutions) of human serum samples from eight individuals with an unknown vaccination history and one sample that was negative (Neg). Twenty-four hours after incubation, the ELVIRA cells were lysed and the luciferase assay was performed. Dilutions with greater than 99% inhibition of luciferase activity relative to virus-only wells were considered neutralized.

**For the HI assay 1 15 000 infectious units/well were incubated with the same dilutions of the serum samples and 1% guinea pig RBCs was added to the serum/virus mixture. The results were evaluated after 30 minutes of incubation at room temperature by comparing the formation of hemagglutination in serum + virus samples with that in control wells that contained RBCs only.

***ELVIRA Flu B Rluc cells were infected with B/Malaysia2506/04 (500 infectious units/well) that had been incubated for 2 hours with dilutions (1:10 followed by twofold serial dilutions) of five human serum samples from individuals with an unknown vaccination history.

†For the HI assay 60 300 infectious units/well were incubated with the same dilutions of the serum samples and 1% guinea pig RBCs added to the serum/virus mixture. The results were evaluated after 30 minutes of incubation at room temperature by comparing the formation of hemagglutination in serum + virus samples with that in control wells that contained RBCs only.

Figure 5. Antiviral susceptibility testing using ELVIRA Flu A-luc and ELVIRA Flu B-Rluc cells Bafilomycin (0–78–30 nm) and amantadine (4–62 μm) were added to ELVIRA® Flu A-luc cells and incubated at 37°C for 30 minutes and then the cells were infected with influenza A or B virus. Luciferase activity was measured after 24 hours. Data expressed as per cent no-drug control. (A) Bafilomycin inhibition curve of influenza A virus (A/MHIA0009) ELVIRA® Flu A-luc cells. (B) Amantadine inhibition curve of influenza A virus (A/MHIA0009) on ELVIRA® Flu A-luc cells. (C) Bafilomycin inhibition of influenza B virus (B/Malaysia/2506/04) on ELVIRA® Flu B-Rluc cells. (D) Amantadine inhibition of influenza B virus (B/Malaysia/2506/04) on ELVIRA® Flu B-Rluc cells.

Methods have also been developed for rapid evaluation of compounds for antiviral activity in 96-well microplates, which include visual quantitation of antiviral activity based upon inhibition of virus-induced CPE or by less subjective colorimetric or fluorometric means. A cell-based screen for potential influenza antivirals that measures the CPE.
induced by influenza virus (A/Udorn/72, H3N2) infection in MDCK cells using the luminescent-based CellTiter Glo system was recently described.\textsuperscript{14} Recently, a viral inhibition assay based on neuraminidase (NA) activity was described and shown to be suitable for high throughput screening to identify potential antiviral compounds or to identify drug-resistant influenza strains.\textsuperscript{37,38} Fluorometric and chemiluminescence NA assays have also been described.\textsuperscript{39,40} The application of the technology described in this report may also be used for primary antiviral screening. One advantage is that the readout is a direct function of viral RNA replication and transcription.

In summary, we have engineered stable cell lines that contain an influenza A virus or influenza B virus-inducible reporter gene that can be used in assays to objectively measure infectious virus titer, antibody neutralization titer, and antiviral drug potency. The cell lines have been maintained for more than 50 passages without loss of inducible reporter enzyme activity. Although further studies are needed to verify the accuracy and precision of this methodology, there is great potential for these assays to replace traditional techniques.

Acknowledgements

We thank the staff of Diagnostic Hybrids, Inc. for providing seasonal influenza virus strains. We gratefully acknowledge the expert technical assistance provided by Melicia Gainey and Ann Wasko of Battelle in Columbus, OH who performed the titer assays on the H5N1 influenza strains. We thank Drs Yung Huang, Dave Scholl, Miguel Quiñones-Mateu for review of the manuscript and helpful suggestions.

This work was supported by NIAID R44AI060312 to PDO and R01AI053629 to AP.

References

1. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008; 121:258–264.
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086–5096.
3. Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Medicine 2007; 4:e15.
4. Update: influenza activity - United States, September 28, 2008 – January 31, 2009. MMWR 2009; 58:115–119.
5. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for pandemic influenza control. Hum Vaccin 2009; 5(3):126–135.
6. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165:265–272.
7. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25:6852–6862.
8. Swine Influenza A (H1N1) infection in two children – Southern California, March-April 2009. MMWR 2009; 58:400–402.
9. Update: infections with a swine-origin influenza A (H1N1) virus United States and other countries, April 28, 2009. MMWR 2009; 58:431–433.
10. Katz JM, Veguilla V, Belser JA et al. The public health impact of avian influenza viruses. Poult Sci 2009; 88:872–879.
11. Tobita K, Sugii K, Enomote C, Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol 1975; 162:9–14.
12. Yoon KJ, Janke BH, Swalla RW, Erickson G. Comparison of a commercial H1N1 enzyme-linked immunosorbent assay and hemagglutination inhibition test in detecting serum antibody against swine influenza viruses. J Vet Diagn Invest 2004; 16:197–201.
13. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990; 28:1308–1313.
14. Noah JW, Severson W, Noah DI, Rasmussen L, White EL, Jonsson CB. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res 2007; 73:50–59.
15. Bachelor LT, Strehl LL, Neubauer RH, PETeway SW Jr, Ferguson BQ. Stable indicator cell lines exhibiting HIV-1 tat function. AIDS Res Hum Retroviruses 1989; 5:275–278.
16. Dorsky DI, Wells M, Harrington RD. Detection of HIV-1 infection with a green fluorescent protein reporter system. J Acquir Immune Defic Syndr Hum Retrov 1996; 13:308–313.
17. Rocancourt D, Bonnerot C, Jouin H, Emerman M, Nicolas JF. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol 1990; 64:2660–2666.
18. Olivo PD. Detection of herpes simplex virus by measurement of luciferase activity in an infected-cell lysate. J Virol Methods 1994; 47:117–128.
19. Olivo PD, Frolov I, Schlesinger S. A cell line that expresses a reporter gene in response to infection by Sindbis virus: a prototype for detection of positive strand RNA viruses. Virol 1994; 198:381–384.
20. Stabell EC, Olivo PD. Isolation of a cell line for rapid and sensitive histochemical assay for the detection of herpes simplex virus. J Virol Methods 1992; 38:195–204.
21. Stabell EC, O’Rourke SR, Storch GA, Olivo PD. Evaluation of a genetically engineered cell line and a histochemical beta-galactosidase assay to detect herpes simplex virus in clinical specimens. J Clin Microbiol 1993; 31:2796–2798.
22. Proffitt MR, Schindler SA. Rapid detection of HSV with an enzyme-linked virus inducible system (ELVIS) employing a genetically modified cell line. Clin Diagn Virol 1995; 4:175–182.
23. Olivo PD, Collins PL, Peeples ME, Schlesinger S. Detection and quantitation of human respiratory syncytial virus (RSV) using minigene cDNA and a Sindbis virus replicon: a prototype assay for negative-strand RNA viruses. Virol 1998; 251:198–205.
24. Lutz A, Dyall J, Olivo PD, Pekosz A. Virus-inducible reporter genes as a tool for detecting and quantifying influenza A virus replication. J Virol Methods 2005; 126:13–20.
25. Neumann G, Zobel A, Hobom G. RNA polymerase I-mediated quantitation of human respiratory syncytial virus molecules. Virol 1994; 202:477–479.
26. Wu WH, Pekosz A. Extending the cytoplasmic tail of the influenza A virus M2 protein leads to reduced virus replication in vivo but not in vitro. J Virol 2008; 82:1059–1063.
27. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493–497.
28 Neumann G, Watanabe T, Kawaoka Y. Plasmid-driven formation of influenza virus-like particles. J Virol 2000; 74:547–551.

29 Zobel A, Neumann G, Hobom G. RNA polymerase I catalysed transcription of insert viral cDNA. Nucleic Acids Res 1993; 21:3607–3614.

30 Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007; 25:4056–4063.

31 Ochiai H, Sakai S, Hirabayashi T, Shimizu Y, Terasawa K. Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antiviral Res 1995; 27:425–430.

32 Felber BK, Pavlakis GN. A quantitative bioassay for HIV-1 based on trans-activation. Science 1988; 239:184–187.

33 Iwatsuki-Horimoto K, Hatta Y, Hatta M et al. Limited compatibility between the RNA polymerase components of influenza virus type A and B. Virus Res 2008; 135:161–165.

34 Bachmann MF, Ecabert B, Kopf M. Influenza virus: a novel method to assess viral and neutralizing antibody titers in vitro. J Immunol Methods 1999; 225:105–111.

35 Frank AL, Puck J, Hughes BJ, Cate TR. Microneutralization test for influenza A and B and paramyxovirus 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 1980; 12:426–432.

36 Smee DF, Morrison AC, Barnard DL, Sidwell RW. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J Virol Methods 2002; 106:71–79.

37 Eichelberger MC, Hassantoufighi A, Wu M, Li M. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Virol J 2008; 5:109.

38 Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 2002; 53:47–61.

39 Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41:742–750.

40 Kiseleva I, Su Q, Toner TJ et al. Cell-based assay for the determination of temperature sensitive and cold adapted phenotypes of influenza viruses. J Virol Methods 2004; 116:71–78.